Loading the session
Loading the session
Loading instrument
$99.60
+1.11%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:46 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +6.7% (SPY −1.6%, XLV +13.5%). 3 months: +125.9% (SPY −0.4%, XLV +15.5%). 1 year: +444.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: KOD, SPY and XLV · as of 4 Nov 2026
Closed at $98.51 on 4 Nov 2026: 5.3% below the 52-week high of $104.00 (1 Oct 2026) and 522.2% above the low of $15.83 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
8.5M shares were sold short at the 15 Oct 2026 settlement, 13.5% of the 62.8M shares outstanding; covering them would take 4.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $98.51 was 46.3% above its 50-day average ($67.32) and 128.2% above its 200-day average ($43.17). It has closed above the 200-day for 28 sessions, since 28 Sep 2026. The 50-day average crossed above the 200-day on 13 Aug 2025, 309 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
4 Nov 2026 volume of 1.0M shares was 0.3× the average of the 30 sessions before it (2.9M), as the price fell 0.4%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
September 28, 2026
+177.96%March 26, 2026
+74.77%February 23, 2022
−80.42%